文 献1）Packer RJ: Brain tumors in children. Arch Neurol 1999; 56(4): 421–5.2）Torres CF, Rebsamen S, Silber JH, Sutton LN, Bilaniuk LT, Zimmerman RA, et al. : Surveillance scanning of children with medulloblastoma. N Engl J Med 1994; 330(13): 892–5.3）Hande KR. Etoposide: four decades of development of a topoisomerase Ⅱ inhibitor. Eur J Cancer 1998; 34(10): 1514-21.4）Slavc I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, et al. Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. Cancer Med 2014; 3(1): 91-100.5）Pajtler KW, Tippelt S, Siegler N, Reichling S, Zimmermann M, Mikasch R, et al. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. J Neurooncol 2016; 128(3): 463-71.6）宮本 裕士.白金製剤．相羽 惠介編．抗がん薬の臨床薬理 第1版．南山堂 2013; 308-9.7）Tippelt S, Mikaschi R, Siegler N, Hilger R.A, Jaehde U, Bode U, et al. Result of pharmacokinetic analysis of intraventricular etoposide in a phase II study of recurrent medulloblastoma, CNS-PNET, and ependymoma. Pediatr Blood Cancer 2015; 62 (Suppl4): S284.8）Cin SN, Zimmerman MA, Yao X, Cohen K, Burger P, Biegel JA, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009; 27(3): 385-9.9）Robinson NJ, Campigotto F, Cin SN, Manley PE, Tumer CD, Zimmerman MA, et al. A phase Ⅱ trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 2014; 61(4): 636-42.10）Chamberlain MC, Tsao-Wei DD, Groshen S. Phase Ⅱ trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 2006; 106(9): 2021-7.11）Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 2001; 84(11): 1453-9.12）Sirisangtragul C, Henke G, Fleischhack G, Reif S, Kloft C, Bode U, et al. Cerebrospinal fluid pharmacokinetics after different dosage regimens of intraventricular etoposide. Int J Clin Pharmacol Ther 2003; 41(12): 606-7.133
元のページ ../index.html#147